Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio per testare la sicurezza e la tollerabilità dell'alprazolam staccato nei partecipanti allo studio di età pari o superiore a 12 anni con crisi epilettiche prolungate stereotipate

24 settembre 2026 aggiornato da: UCB Biopharma SRL

Uno studio di estensione in aperto, multicentrico, ambulatoriale per valutare la sicurezza e la tollerabilità dell'alprazolam staccato nei partecipanti allo studio di età pari o superiore a 12 anni con crisi epilettiche prolungate stereotipate

The purpose of the study is to evaluate the long-term safety and tolerability of Staccato alprazolam.

Panoramica dello studio

Stato

Iscrizione su invito

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

300

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Australia
      • Fitzroy, Australia
        • Ep0165 30016
      • Herston, Australia
        • Ep0165 30030
      • South Brisbane, Australia
        • Ep0165 30031
  • Bulgaria
      • Blagoevgrad, Bulgaria
        • Ep0165 40650
      • Pazardzhik, Bulgaria
        • Ep0165 40708
      • Pleven, Bulgaria
        • Ep0165 40665
      • Sofia, Bulgaria
        • Ep0165 40651
  • Cechia
      • Brno, Cechia
        • Ep0165 40670
      • Ostrava - Poruba, Cechia
        • Ep0165 40672
      • Prague, Cechia
        • Ep0165 40063
      • Prague, Cechia
        • Ep0165 40671
      • Prague, Cechia
        • Ep0165 40714
  • Cina
      • Beijing, Cina
        • Ep0165 20246
      • Beijing, Cina
        • Ep0165 20268
      • Beijing, Cina
        • Ep0165 20299
      • Changchun, Cina
        • Ep0165 20261
      • Chengdu, Cina
        • Ep0165 20133
      • Chengdu, Cina
        • Ep0165 20137
      • Chongqing, Cina
        • Ep0165 20334
      • Fuzhou, Cina
        • Ep0165 20179
      • Guangzhou, Cina
        • Ep0165 20264
      • Guangzhou, Cina
        • Ep0165 20269
      • Guangzhou, Cina
        • Ep0165 20124
      • Guangzhou, Cina
        • Ep0165 20300
      • Hangzhou, Cina
        • Ep0165 20022
      • Kunming, Cina
        • Ep0165 20320
      • Lanzhou, Cina
        • Ep0165 20258
      • Nanjing, Cina
        • Ep0165 20267
      • Nanning, Cina
        • Ep0165 20331
      • Qingdao, Cina
        • Ep0165 20333
      • Shanghai, Cina
        • Ep0165 20292
      • Shijiazhuang, Cina
        • Ep0165 20289
      • Suzhou, Cina
        • Ep0165 20119
      • Tianjin, Cina
        • Ep0165 20257
      • Wenzhou, Cina
        • Ep0165 20025
      • Zhanjiang, Cina
        • Ep0165 20262
      • Zhengzhou, Cina
        • Ep0165 20251
  • Germania
      • Berlin, Germania
        • Ep0165 40683
      • Bielefeld, Germania
        • Ep0165 40685
      • Erlangen, Germania
        • Ep0165 40023
      • Frankfurt am Main, Germania
        • Ep0165 40645
      • Marburg, Germania
        • Ep0165 40529
  • Giappone
      • Fukuoka, Giappone
        • Ep0165 20248
      • Hachioji-shi, Giappone
        • Ep0165 20070
      • Hiroshima, Giappone
        • Ep0165 20249
      • Hōfu, Giappone
        • Ep0165 20236
      • Itami, Giappone
        • Ep0165 20239
      • Kodaira, Giappone
        • Ep0165 20143
      • Koshi-shi, Giappone
        • Ep0165 20315
      • Kyoto, Giappone
        • Ep0165 20147
      • Niigata, Giappone
        • Ep0165 20238
      • Osaka, Giappone
        • Ep0165 20302
      • Sapporo, Giappone
        • Ep0165 20316
      • Shimotsuga-gun, Giappone
        • Ep0165 20337
      • Shinjuku-ku, Giappone
        • Ep0165 20297
      • Shizuoka, Giappone
        • Ep0165 20240
      • Suita, Giappone
        • Ep0165 20242
      • Tōon, Giappone
        • Ep0165 20266
      • Yamagata, Giappone
        • Ep0165 20244
      • Ōmura, Giappone
        • Ep0165 20241
  • Italia
      • Genova, Italia
        • Ep0165 40674
      • Milan, Italia
        • Ep0165 40144
      • Pavia, Italia
        • Ep0165 40477
      • Roma, Italia
        • Ep0165 40257
      • Roma, Italia
        • Ep0165 40675
  • Polonia
      • Bydgoszcz, Polonia
        • Ep0165 40707
      • Gdansk, Polonia
        • Ep0165 40677
      • Krakow, Polonia
        • Ep0165 40842
      • Lublin, Polonia
        • Ep0165 40676
      • Nowa Sól, Polonia
        • Ep0165 40091
      • Świdnik, Polonia
        • Ep0165 40678
  • Regno Unito
      • Birmingham, Regno Unito
        • Ep0165 40686
      • Glasgow, Regno Unito
        • Ep0165 40735
      • London, Regno Unito
        • Ep0165 40833
      • Oxford, Regno Unito
        • Ep0165 40163
      • Salford, Regno Unito
        • Ep0165 40108
  • Spagna
      • Barcelona, Spagna
        • Ep0165 40160
      • L'Hospitalet de Llobregat, Spagna
        • Ep0165 40157
      • Madrid, Spagna
        • Ep0165 40540
      • Pamplona, Spagna
        • Ep0165 40352
      • Seville, Spagna
        • Ep0165 40668
      • Terrassa, Spagna
        • Ep0165 40453
      • Valencia, Spagna
        • Ep0165 40230
      • Valladolid, Spagna
        • Ep0165 40667
  • Stati Uniti
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85004
        • Ep0165 50506
      • Scottsdale, Arizona, Stati Uniti, 85253
        • Ep0165 50720
    • Arkansas
      • Little Rock, Arkansas, Stati Uniti, 72205
        • Ep0165 50494
    • California
      • Downey, California, Stati Uniti, 90242
        • Ep0165 50118
      • La Jolla, California, Stati Uniti, 92037
        • Ep0165 50416
      • Long Beach, California, Stati Uniti, 90806
        • Ep0165 50702
      • Poway, California, Stati Uniti, 92064
        • Ep0165 50722
      • Sacramento, California, Stati Uniti, 95817
        • Ep0165 50716
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20037
        • Ep0165 50088
    • Florida
      • Gulf Breeze, Florida, Stati Uniti, 32561
        • Ep0165 50515
      • Jacksonville, Florida, Stati Uniti, 32224
        • Ep0165 50342
      • Jacksonville, Florida, Stati Uniti, 32209-6533
        • Ep0165 50508
      • Miami, Florida, Stati Uniti, 33136
        • Ep0165 50199
      • Miami, Florida, Stati Uniti, 33176
        • Ep0165 50676
      • Orlando, Florida, Stati Uniti, 32806
        • Ep0165 50509
      • Rockledge, Florida, Stati Uniti, 32955
        • Ep0165 50703
      • Tampa, Florida, Stati Uniti, 33606
        • Ep0165 50308
    • Hawaii
      • Honolulu, Hawaii, Stati Uniti, 96817
        • Ep0165 50323
    • Idaho
      • Boise, Idaho, Stati Uniti, 83702
        • Ep0165 50512
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60611
        • Ep0165 50493
    • Indiana
      • Fort Wayne, Indiana, Stati Uniti, 46845
        • Ep0165 50504
    • Louisiana
      • New Orleans, Louisiana, Stati Uniti, 70122
        • Ep0165 50517
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Ep0165 50047
      • Boston, Massachusetts, Stati Uniti, 02118
        • Ep0165 50615
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63110
        • Ep0165 50507
    • New Jersey
      • New Brunswick, New Jersey, Stati Uniti, 08901
        • Ep0165 50299
    • New York
      • Amherst, New York, Stati Uniti, 14226
        • Ep0165 50497
      • New Hyde Park, New York, Stati Uniti, 11042
        • Ep0165 50625
      • New York, New York, Stati Uniti, 10016
        • Ep0165 50298
      • New York, New York, Stati Uniti, 10029
        • Ep0165 50490
      • New York, New York, Stati Uniti, 10075
        • Ep0165 50518
      • Rochester, New York, Stati Uniti, 14642
        • Ep0165 50034
    • North Carolina
      • Charlotte, North Carolina, Stati Uniti, 28204
        • Ep0165 50514
      • Durham, North Carolina, Stati Uniti, 27705
        • Ep0165 50715
    • Oregon
      • Portland, Oregon, Stati Uniti, 97239
        • Ep0165 50701
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Ep0165 50096
      • Philadelphia, Pennsylvania, Stati Uniti, 19107
        • Ep0165 50364
      • Philadelphia, Pennsylvania, Stati Uniti, 19140
        • Ep0165 50089
      • Pittsburgh, Pennsylvania, Stati Uniti, 15212
        • Ep0165 50511
      • Pittsburgh, Pennsylvania, Stati Uniti, 15213
        • Ep0165 50491
    • Tennessee
      • Chattanooga, Tennessee, Stati Uniti, 37403
        • Ep0165 50700
      • Memphis, Tennessee, Stati Uniti, 38103-2800
        • Ep0165 50513
      • Nashville, Tennessee, Stati Uniti, 37232
        • Ep0165 50103
    • Texas
      • Austin, Texas, Stati Uniti, 78749
        • Ep0165 50731
      • Houston, Texas, Stati Uniti, 77459
        • Ep0165 50525
      • Houston, Texas, Stati Uniti, 77030
        • Ep0165 50714
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84132
        • Ep0165 50473
    • Virginia
      • Winchester, Virginia, Stati Uniti, 22601
        • Ep0165 50726
  • Ungheria
      • Balassagyarmat, Ungheria
        • Ep0165 40666
      • Budapest, Ungheria
        • Ep0165 40673
      • Budapest, Ungheria
        • Ep0165 40704
      • Debrecen, Ungheria
        • Ep0165 40653

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

12 anni e precedenti (Bambino, Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion criteria:

  • Participant must be ≥12 years of age at the time of signing informed consent

  • Participant must have a study caregiver ≥18 years of age at the time of signing the informed consent; the study caregiver(s) must be able to recognize and observe the participant's seizures

  • Participants with an established diagnosis of focal or generalized epilepsy or combined focal and generalized epilepsy with a documented history of stereotypical episodes of prolonged seizures that includes at least 1 of the following:

    1. Generalized seizure episodes starting with a flurry of absence seizures or myoclonic seizures with a minimum total duration of 5 minutes
    2. Episodes of a focal seizure with a minimum duration of 3 minutes
    3. Episodes of a focal seizure or a flurry of myoclonic seizures for at least 90 seconds followed by a generalized/bilateral tonic-clonic seizure with a minimum total duration of 3 minutes

  • Prior to the Screening Visit, participant completed a study using Staccato alprazolam (such as EP0162 (NCT05077904), ENGAGE-E-001 (NCT03478982), or UP0100 (NCT04857307))

Exclusion Criteria:

  • Participant has a current history of alcohol or drug use disorder, as defined in the Diagnostic and Statistical Manual of Mental Disorders 5, within the previous 1 year
  • Participant has a known hypersensitivity to any components of the investigational medicinal product (IMP) or comparable drugs (and/or an investigational device) as stated in this protocol or to albuterol (or similar bronchospasm rescue medication if needed to meet country-specific requirements)
  • Participant has a history of convulsive (generalized tonic-clonic) status epilepticus in the 8 weeks prior to the Screening Visit
  • Participant has a history or presence of known nonepileptic seizures which cannot be distinguished from qualifying epileptic seizures
  • Participant has a clinically significant known airway hypersensitivity (eg, bronchospasm to known allergens, such as pollen, animals, or food) and/or acute respiratory signs/symptoms (eg, shortness of breath, wheezing on lung auscultation). NOTE: Participants with mild asthma who qualify for inclusion in the are allowed to be enrolled even though they have known airway hypersensitivity
  • Participant has a clinically significant chronic pulmonary disorder other than mild asthma (eg, chronic obstructive pulmonary disease, restrictive lung diseases [including idiopathic pulmonary fibrosis]) and/or recent history or presence of hemoptysis or pneumothorax
  • Participant has had a positive antigen test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and experienced moderate to severe signs/symptoms of respiratory distress necessitating hospitalization or outpatient treatment such as ambulatory oxygen, extensive treatment with inhaler medications, and/or oral medications for a duration of 4 weeks or more, unless full resolution occurred at least 6 months prior to Screening
  • Participant has experienced a severe upper respiratory tract infection within 4 weeks or severe bronchitis/pneumonia within 3 months before the Screening Visit
  • Participant has a history or presence of acute narrow-angle glaucoma
  • Participant has a condition for which oral alprazolam is contraindicated as per the regional labeling
  • Participant is taking any drug that is a strong CYP3A4 inhibitor, including azole antifungal agents (ketoconazole and itraconazole) and nefazodone
  • Participant is taking any opioids or sedative hypnotics on a chronic basis
  • Participant is taking nonselective beta blockers on a chronic basis

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Staccato alprazolam

Participants will receive Staccato alprazolam by inhalation.
Droga: Staccato alprazolam
  • Pharmaceutical form: Inhalation powder
  • Route of administration: Inhalation

Participants will receive Staccato alprazolam during the Treatment Period.

Altri nomi:
  • UCB7538

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Frequency of treatment-emergent adverse events (TEAEs)
Lasso di tempo: From Baseline up to the End of Study Visit (up to 78 months)

An Adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medical product (IMP) and whether anticipated or unanticipated. A treatment-emergent adverse event (TEAE) is defined as any AE with a start date/time on or after the first IMP administration.
From Baseline up to the End of Study Visit (up to 78 months)
Frequency of TEAEs leading to withdrawal from study
Lasso di tempo: From Baseline up to the End of Study Visit (up to 78 months)

An Adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medical product (IMP) and whether anticipated or unanticipated. A treatment-emergent adverse event (TEAE) is defined as any AE with a start date/time on or after the first IMP administration.
From Baseline up to the End of Study Visit (up to 78 months)
Frequency of serious TEAEs
Lasso di tempo: From Baseline up to the End of Study Visit (up to 78 months)

A serious adverse event (SAE) is any untoward medical occurrence that at any dose:

  • Results in death
  • Is life-threatening
  • Requires inpatient hospitalisation or prolongation of existing hospitalisation
  • Results in persistent or significant disability/incapacity, or
  • Is a congenital anomaly/birth defect
  • Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above
From Baseline up to the End of Study Visit (up to 78 months)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Treatment success after investigational medicinal product (IMP) administration for seizures occurring within the first 12 months
Lasso di tempo: From start of IMP treatment up to 12 months

A responder after up to a maximum of 10 treated seizures will be defined as having a termination of seizure within 90 seconds after IMP dministration.
From start of IMP treatment up to 12 months
Treatment success after IMP administration with no recurrence after 2 hours for seizures during the first 12 months
Lasso di tempo: From start of IMP treatment up to 12 months

A responder after up to a maximum of 10 treated seizures will be defined as termination of seizure within 90 seconds after IMP administration and no recurrence of seizure(s) from IMP administration to 2 hours after IMP administration and no initiation of seizure rescue treatment from 90 seconds to 2 hours after IMP administration.
From start of IMP treatment up to 12 months
Frequency of respiratory TEAEs
Lasso di tempo: From Baseline up to the End of Study Visit (up to 78 months)

An Adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medical product (IMP) and whether anticipated or unanticipated. A treatment-emergent adverse event (TEAE) is defined as any AE with a start date/time on or after the first IMP administration.
From Baseline up to the End of Study Visit (up to 78 months)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

UCB Biopharma SRL

Investigatori

  • Direttore dello studio: UCB Cares, 001 844 599 2273 (UCB)

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

3 febbraio 2022

Completamento primario (Stimato)

30 novembre 2028

Completamento dello studio (Stimato)

30 novembre 2028

Date di iscrizione allo studio

Primo inviato

30 settembre 2021

Primo inviato che soddisfa i criteri di controllo qualità

30 settembre 2021

Primo Inserito (Effettivo)

13 ottobre 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

25 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

24 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • EP0165
  • 2021-002637-42 (Numero EudraCT)
  • 2023-508868-30 (Identificatore di registro: EU Clinical Trials)
  • U1111-1299-3027 (Altro identificatore: Universal Trial Number (UTN))
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of reidentifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Periodo di condivisione IPD

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Criteri di accesso alla condivisione IPD

Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi